AbbVie to Acquire Allergan

Published on: 

Applied Clinical Trials

AbbVie Inc. and Allergan plc have announced that they have entered into a definitive transaction agreement under which AbbVie will acquire Allergan for approximately $63 billion. The combined company will consist of several franchises with focus across immunology, hematologic oncology, medical aesthetics, neuroscience, women's health, eye care, and virology.

Learn all about the acquisition, right here.